AEON Biopharma Slashes Debt by Over 90% with Strategic Transactions
AEON Biopharma Inc. announced strategic transactions in November 2025, including a $6 million PIPE financing and a proposed note exchange with Daewoong Pharmaceutical, to reduce its debt by over 90%. These actions aim to strengthen its balance sheet, extend its cash runway into Q2 2026, and accelerate the ABP-450 biosimilar program development by up to six months.
AEON Biopharma Inc. announced two complementary transactions in November 2025: a $6 million PIPE financing and a proposed note exchange with Daewoong Pharmaceutical. These moves are expected to reduce AEON’s outstanding debt by more than 90%, strengthen its balance sheet, and extend its cash runway into the second quarter of 2026. The transactions are also anticipated to accelerate the development of AEON’s ABP-450 biosimilar program by up to six months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AEON Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001837607-25-000084), on November 14, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
